

Celltrion's Biosimilar to Remicade Likely to be Approved for All Indications

February 12, 2016

ATTORNEYS

Ropka, PhD, Stacie

Randi Hernandez

PharmTech.com / BioPharm International

Axinn counsel Stacie Ropka was quoted in the PharmTech.com and BioPharm International article, "Celltrion's Biosimilar to Remicade Likely to be Approved for All Indications."